⌘K
t
On 31 October 2024, Creo Medical Group plc announced that its total issued share capital consists of 412,148,979 Ordinary Shares of 0.1 pence each. The Company confirmed it does not hold any Ordinary Shares in Treasury, resulting in a total of 412,148,979 voting rights.
| Date | 31 Oct 2024 |
| Time | 16:36:03 |
| Category | Capital structure |
| ID | 4773K |
("Creo", the "Group" or the "Company")
Total Voting Rights
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company's total issued share capital consists of 412,148,979 Ordinary Shares of 0.1 pence each ("Ordinary Shares") with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of voting rights in the Company is 412,148,979. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
|
Creo Medical Group plc |
|
|
Richard Rees (CFO) Richard Craven (Company Secretary) |
Via Walbrook PR |
|
|
|
|
Cavendish Capital Markets Limited |
+44 (0)20 7220 0500 |
|
Stephen Keys / Camilla Hume / George Lawson (NOMAD) |
|
|
Michael Johnson (Sales) |
|
|
|
|
|
Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown |
+44 (0)20 7260 1000 |
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
Paul McManus / Alice Woodings / Phillip Marriage |
Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 / +44 (0)7867 984 082 |
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
